EluNIR Ridaforolimus Eluting Coronary Stent System LUN250R15USRecalls & reported problems
Medinol Ltd. · Class 3 · Implant
All models of EluNIR Ridaforolimus Eluting Coronary Stent System (27)
Data updated Oct 18, 2026 from official FDA records · Editorial policy
- Adverse event reports
- 1
- Deaths reported
- 0
- Injuries reported
- 1
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 07290107013536), received between Sep 13, 2018 and Sep 13, 2018 — classified as 1 injury.
The most frequently reported specific device problem is “Device Dislodged or Dislocated” (1 report).
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.
Most reported problems
Device problems
- Device Dislodged or Dislocated1
Patient problems
- No Consequences Or Impact To Patient1
Recent adverse event reports
The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.
InjurySep 13, 2018Device Dislodged or Dislocated; Device Dislodged or Dislocated
INITIAL DESCRIPTION OF EVENT: THE STENT DISLODGED OFF THE PTCA. IT WAS DEPLOYED IN THE LAD. THE PATIENT WAS NOT HURT. ANOTHER STENT WAS USED. ADDITIONAL INFORMATION RECEIVED: INFORMATION RECEIVED FROM CORDIS ON AUG. 21, 2018: THE INTENDED TARGET LESION WAS FIRST DIAG. THE TARGET LESION CHARACTERISTIC WAS: 95% STENOSIS, VERY CALCIFIED AND NOT TORTUOUS. THE DISLODGMENT OCCURRED DURING THE WITHDRAWAL BACK TO THE GUIDE CATHETER. THERE WAS AN ATTEMPT TO INTENTIONALLY DEPLOY THE STENT/INFLATE THE BALLOON. THE SDS IS NOT AVAILABLE FOR INSPECTION, THEY THREW THE PTCA AWAY. THERE WAS NO OTHER PRODUCT ISSUE NOTED EITHER AT THE ACCOUNT, AFTER THE PROCEDURE OR PRIOR TO SHIPPING FOR INSPECTION. PATIENT INFORMATION IS NOT AVAILABLE. THE PRODUCT WAS PREPPED PROPERLY PER THE IFU. THERE WERE NO PROBLEMS NOTED DURING PREPARATION. THE PROCEDURE COMPLETE BY DEPLOYING THE STENT IN THE PROX LAD AND ANOTHER ELUNIR WAS USED IN DISTAL LAD. THE PROCEDURE COMPLETED SUCCESSFULLY WITHOUT PATIENT INJURY. THE PRODUCT WAS STORED PROPERLY PER THE INSTRUCTIONS FOR USE (IFU). THERE WAS NO DAMAGE NOTED TO THE PRODUCT PACKAGING UPON INSPECTION PRIOR TO USE. THERE WAS NO REPORTED DIFFICULTY REMOVING THE PRODUCT FROM TH
Patient problems: No Consequences Or Impact To Patient
MAUDE report 7872121 ↗
Other Coronary Drug-Eluting Stent devices
- SYNERGY™ H7493926038300Boston Scientific Corporation · Coronary drug-eluting stent8 deaths124 reports
- SYNERGY™ H7493926016300Boston Scientific Corporation · Coronary drug-eluting stent7 deaths106 reports
- SYNERGY™ H7493926020300Boston Scientific Corporation · Coronary drug-eluting stent9 deaths90 reports
- SYNERGY™ H7493926016250Boston Scientific Corporation · Coronary drug-eluting stent6 deaths82 reports
- XIENCE Sierra™ 1550350-33Abbott Vascular Inc. · Coronary drug-eluting stent1 recall32 reports
- Resolute Onyx™ RONYX30022UXMedtronic, Inc. · Coronary drug-eluting stent6 deaths76 reports
- SYNERGY™ H7493926024300Boston Scientific Corporation · Coronary drug-eluting stent3 deaths75 reports
- Resolute Onyx™ RONYX30015UXMedtronic, Inc. · Coronary drug-eluting stent3 deaths73 reports
Sources and updates
- Device record: FDA GUDID, file dated Oct 13, 2026 · View this device in AccessGUDID ↗
- Adverse event reports: FDA MAUDE, file dated Oct 14, 2026 · each report above links to its original FDA record
- Recalls: FDA Medical Device Recalls, file dated Oct 16, 2026
- Page last rebuilt: Oct 18, 2026. Data downloaded through openFDA, which notes it is not validated for clinical or regulatory use.
How reports and recalls are matched · Editorial policy · Report an error on this page